Aditxt, Inc. Financial Instrument Subject to Mandatory Redemption, Maturity, Year Three
Aditxt, Inc. (ADTX) had Financial Instrument Subject to Mandatory Redemption, Maturity, Year Three of $4 as of 2021-01-25, per its 10-Q filed 2021-08-12.
Discontinued › Notes › Financial Services › Federal Home Loan Banks
us-gaap:FinancialInstrumentsSubjectToMandatoryRedemptionRedeemableInYearThree · last filed 2021-08-12
- 2021-01-25: Financial Instrument Subject to Mandatory Redemption, Maturity, Year Three $4.00.
| Period end | Financial Instrument Subject to Mandatory Redemption, Maturity, Year Three |
|---|---|
| 2021-01-25 | $4.00 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |